The Kasralainy Nephrology Group (KANG) clinical recommendations present a structured framework for assessing kidney disease patients across diverse clinical phenotypes, guiding the use of SGLT2 inhibitors in conditions commonly encountered in nephrology practice (Fig. 1) (Table 3). The gene discussed is SLC5A2; the disease is kidney disorder.